Altered gene expression in cells from patients with lysosomal storage disorders suggests impairment of the ubiquitin pathway.
about
The diagnosis of inherited metabolic diseases by microarray gene expression profilingUbiquitin C-terminal hydrolase L1 (UCH-L1): structure, distribution and roles in brain function and dysfunctionGenetic dissection of a cell-autonomous neurodegenerative disorder: lessons learned from mouse models of Niemann-Pick disease type CNeuroinflammation, mitochondrial defects and neurodegeneration in mucopolysaccharidosis III type C mouse model.Neuraminidase-1: a novel therapeutic target in multistage tumorigenesisUCHL1 deficiency exacerbates human islet amyloid polypeptide toxicity in β-cells: evidence of interplay between the ubiquitin/proteasome system and autophagyβ-cell dysfunctional ERAD/ubiquitin/proteasome system in type 2 diabetes mediated by islet amyloid polypeptide-induced UCH-L1 deficiency.Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder--murine Pompe disease.Epidermal growth factor cytoplasmic domain affects ErbB protein degradation by the lysosomal and ubiquitin-proteasome pathway in human cancer cells.Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease.Differential effects of Usp14 and Uch-L1 on the ubiquitin proteasome system and synaptic activity.Reversibility of neuropathology in Tay-Sachs-related diseases.Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond.Genetic convergence of Parkinson's disease and lysosomal storage disorders.Molecular diagnosis of parathyroid carcinoma: a reality in the near future.Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity.Cathepsin D is one of the major enzymes involved in intracellular degradation of AGE-modified proteins.Parkinsonism in Inherited Metabolic Disorders: Key Considerations and Major Features
P2860
Q21202878-C7ADFD8F-331F-4258-BDAA-7A14967837DEQ26741828-B31EFF05-7B48-4D15-8603-B2C3AFF36DFAQ27006043-B9C9AFC6-36B5-4C33-A4C8-A49D09B978B3Q27303930-5B8F7751-8FCC-432E-BC3F-39EDE8416F0AQ28066130-67CF48F8-0304-422D-B017-E77A3D37EC86Q28118734-6196D518-F552-4D6E-9427-3E8891995277Q34448671-A7F1E08B-986C-4315-A39F-D2E29C539B9DQ34577206-6DFA4A42-5831-443B-A2CF-40FBC726B03BQ36062148-9BF64B4A-688D-4C9E-81DE-09BCF98FF8EEQ37117422-93596A69-A15F-4176-98F1-1C828602D950Q37325929-9540CF84-C87F-40A8-B830-F051D4E6E3D3Q37463989-99AC7B64-7CB7-41F7-96EB-20411330614DQ37880734-8DB18103-A7A9-41F2-ABB0-5BB2F1AA7CE5Q38237560-4934346F-EF2E-4E0C-8107-5B68BC821D8AQ39670916-95B44F26-C6F7-4BCF-9090-F2CC6CD410D9Q39914071-C9A148CF-E360-49F4-8419-E6AAA1D1E290Q43013056-56CCC345-7844-48D2-BCF9-1B191C64ED77Q58122613-B590FB68-AA80-435D-9870-144CDD9A1CD7
P2860
Altered gene expression in cells from patients with lysosomal storage disorders suggests impairment of the ubiquitin pathway.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Altered gene expression in cel ...... ment of the ubiquitin pathway.
@en
Altered gene expression in cel ...... ment of the ubiquitin pathway.
@nl
type
label
Altered gene expression in cel ...... ment of the ubiquitin pathway.
@en
Altered gene expression in cel ...... ment of the ubiquitin pathway.
@nl
prefLabel
Altered gene expression in cel ...... ment of the ubiquitin pathway.
@en
Altered gene expression in cel ...... ment of the ubiquitin pathway.
@nl
P2093
P2860
P356
P1476
Altered gene expression in cel ...... ment of the ubiquitin pathway.
@en
P2093
A V Pshezhetsky
L Ashmarina
R A Gravel
V Seyrantepe
P2860
P2888
P304
P356
10.1038/SJ.CDD.4402013
P577
2006-08-04T00:00:00Z